Logotype for Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company (4502) Q2 2027 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Takeda Pharmaceutical Company Limited

Q2 2027 earnings summary

29 Oct, 2026

Executive summary

  • H1 FY2026 revenue was JPY 2,407.0B, up 8.4% reported but down 1.0% CER; core operating profit rose 11.2% reported and 0.7% CER to JPY 710.6B.

  • Transformation savings helped fund launches and R&D; FY2026 core operating profit guidance increased to JPY 1,190B, mainly on FX benefits.

Financial highlights

  • H1 reported operating profit rose 60.4% to JPY 406.7B; net profit attributable to owners was JPY 305.6B, up 171.8% reported.

  • H1 core net profit was JPY 489.6B, up 11.6% reported and down 0.2% CER; core EPS was JPY 308, up 10.5% reported and down 1.2% CER.

  • Q2 revenue was JPY 1,187.1B, down 1.6% CER; core operating profit was JPY 351.7B, up 1.9% CER.

  • H1 operating cash flow was JPY 431.9B, down 27.2%; adjusted free cash flow was JPY 325.7B, down 38.0%.

Outlook and guidance

  • FY2026 revenue guidance rose JPY 60B to JPY 4,700B; the low-single-digit CER decline outlook was maintained.

  • Core operating profit guidance increased JPY 30B to JPY 1,190B and core EPS to JPY 482, mainly reflecting transactional FX benefits.

  • Reported operating profit guidance rose to JPY 453B, net profit to JPY 209B and basic EPS to JPY 131; adjusted FCF guidance increased to JPY 700B–800B.

  • CER guidance indicates mid-single-digit core operating profit decline and low-teens core EPS decline; stronger LOE-affected and mature-portfolio revenue is partly offset by Albumin and QDENGA weakness.

  • FY2026 restructuring costs are forecast at JPY 160B; CAPEX guidance is JPY 330B–380B and annual dividend guidance remains JPY 204 per share.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Takeda Pharmaceutical Company